CeriBell, Inc. (CBLL) Stock Score, Valuation & Financial Research
CeriBell, Inc. is in the Healthcare sector and Medical - Devices industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 26/100.
Quick answer for CBLL
CeriBell, Inc. currently has a Wall Street Score of 26/100. The stored market price is $24.5. Its financial score is 25/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What CeriBell, Inc. does
CeriBell, Inc. specializes in pioneering artificial intelligence (AI)-powered electroencephalography (EEG) solutions designed for the immediate diagnosis and treatment of neurological conditions directly at the patient's bedside. The company's primary offering is the Ceribell System, an innovative, on-site EEG platform engineered to fulfill crucial, previously unmet requirements for patients in urgent medical environments. Beyond the core system, CeriBell also provides single-use EEG headbands and compact, battery-powered recording devices. Originally established in 2014 as Brain Stethoscope, Inc., the company underwent a name change to CeriBell, Inc. in August 2015. Its headquarters are located in Sunnyvale, California.
CBLL financial snapshot
- Wall Street Score:
- 26/100
- Current price:
- $24.5
- Market capitalization:
- $929.6M
- Revenue:
- $102.0M
- Net income:
- $-66.0M
- Free cash flow:
- $-41.6M
- Cash:
- $32.7M
- Total debt:
- $21.9M
- EPS:
- -1.76
- Financial score:
- 25/100
- Valuation score:
- 0/100
- Revenue score:
- 36/100
What stands out
- Reported year-over-year revenue growth is +0.1%.
- Free cash flow is $-41.6M, showing cash burn in the current stored period.
- The balance sheet shows $32.7M of cash versus $21.9M of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 25/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-14.
How to research CBLL
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.